Investing.com - Financial Markets Worldwide
🔴 LIVE: The Secrets of ProPicks AI Success Revealed + November’s List FREEWatch Now

UPDATE 1-Citron's Left discloses short position in Mallinckrodt

Published 2015-11-10, 03:25 p/m
© Reuters. UPDATE 1-Citron's Left discloses short position in Mallinckrodt
BHC
-
MNKKQ
-

(Adds Mallinckrodt (N:MNK) response; updates shares)
Nov 10 (Reuters) - Influential short-seller Citron
Research's Andrew Left, who accused Mallinckrodt Plc MNK.N of
being an offender of the reimbursement system, told CNBC on
Tuesday that he has a short position on the company's stock.
Mallinckrodt's stock plunged 26 percent on Monday after
Left's tweet on the drugmaker. urn:newsml:reuters.com:*:nL3N1345LP
However, the stock recovered on Tuesday and were up 8.11
percent at $62.71 in late afternoon trading as Left did not lay
out specific accusations against the company.
Left, in the interview to CNBC, accused Mallinckrodt's Chief
Executive Mark Trudeau of misrepresenting the efficacy of the
drugmaker's biggest product, Acthar.
Acthar, which has been in the U.S. market for the past 65
years, accounted for about 28 percent of Mallinckrodt's latest
quarterly revenue of $965.1 million.
Mallinckrodt gained rights to Acthar Gel through its
acquisition of Questcor Pharmaceuticals Inc for about $5.6
billion in 2014.
Trudeau called the short-seller's accusations "completely
false" in an interview with CNBC.
Citron published a scathing report on Valeant
Pharmaceuticals International Inc VRX.TO VRX.N late October,
accusing the Canadian drugmaker of using specialty pharmacies to
inflate revenue. Shares plunged 40 percent on the day.
"My short on Valeant has been significantly scaled down from
where it was earlier," Left told CNBC on Tuesday.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.